Project

Finch 302 Gilead

Completed · 2017 until 2018

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2017
End Date
2018
Financing
Industry
Keywords
Filgotinib, active RA, inadequate Response to biologic DMARD Therapy
Brief description/objective

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase
3 Study to Assess the Efficacy and Safety of Filgotinib Administered
for 24 weeks in Combination with Conventional Synthetic
Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects
with Moderately to Severely Active Rheumatoid Arthritis Who Have
an Inadequate Response to Biologic DMARD(s) Treatment